Galapagos strong outperformer biotech sector

In the recent years Galapagos was very succesful for investors. Because of the massive return over the past 10 years of 1061 percent the share belongs to the top of the biotech companies. Shares of the sector yielded the past 10 years a gain of at around 241 percent.

Returns Galapagos versus biotech sector

stock graphs

Returns stock Galapagos over several periods, excluding dividend returns

Since 2012 the stock has a price gain of 122 percent. over the past 90 days the stock made a loss of 33 percent.

Core figures European biotech sector

stock prices

On average the sector trades costs now 35 times the earnings per share. The sector trades at 4,73 times the book value per share. The returns since 2007 are +241 percent and since 2012 +202 percent.

For this year Galapagos's revenue will be around 554,09 million euros. This is according to the average of the analysts' estimates. This is rather significant lower than 2019's revenue of 895,89 million euros.

Historical revenues and results Galapagos plus estimates 2020

historische koersen

Galapagos Belgie ©


The analysts expect for 2020 a net loss of 163 million euros. For this year most of the analysts expect a loss per share of 2,43 euros. The PE-ratio therefore is -50,19.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies is a limited 0,06 percent.

Recent target prices around 142 euros

The most recent recommendations for the biotech company are from DeGroof Petercam, Bryan Garnier and Barclays.

Galapagos's market value equals around 6,64 billion . The Galapagos stock was the past 12 months quite volatile. Since last August the stock is 19 percent lower. This year the stock price moved between 105 and 253 euro.

Historical stock prices Galapagos

fundamental data galapagos

Click here for dividend Galapagos. At 12.39 the stock trades 4,14 percent lower at 121,95 euros. Nieuwsdienst: +31 084-0032-842

Copyright B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.